1st OCULAR BLOOD FLOW SUMMIT: CONGRESS REPORT
DR RONALD GERSTE
Introduction
The relationship between ocular circulation and various eye diseases has been studied intensively in recent years which were also made possible by the introduction of new examination methods. This applies to "classical" vascular diseases such as retinal vascular occlusions or diabetic retinopathy but above all to glaucoma. The vascular component of this optic neuropathy has been studied primarily in Switzerland and the pathogenetic concept of glaucoma, developed by Professor Josef Flammer (long-time director of the University Eye Hospital Basel) has led to a better understanding of this disease.
Mount Rigi |
In
view of Switzerland's pioneering achievements, it is only logical that the
first Ocular Blood Flow Summit took place in the heart of the Central European
country - whereby "Summit" was true in two respects: on the one hand,
the program director Dr. Katarzyna Konieczka (Basel) had ensured that leading
scientists in the field of ocular perfusion came together for this meeting. On
the other hand, it took place almost at summit height: on Mount Rigi, not far
from Lucerne, at 1400 meters (approx. 4600 feet) altitude. Below are a few
practical highlights of the four-day congress.
Glaucoma:
The pathogenetic concept of optic nerve damage
Professor
Josef Flammer described a part of his medical life's work, the role of blood
flow in the pathogenesis of glaucoma. The disease affects the entire optical
pathway, from thinning of the optic nerve to cell loss in the lateral
geniculate nucleus and the visual cortex. Blood flow is reduced particularly in
normal tension glaucoma (NTG) patients but also in those high-pressure glaucoma
patients, which progress despite a normalized IOP. A reduction was measured not
only in the retina, choroid, optic nerve head and in its vicinity, but also in
retrobulbar vessels and even in the nail fold capillaries. The capillary
microscopy of the nail fold led to the discovery of the relationship between
peripheral vasospasm and disturbed regulation of ocular blood flow. In
glaucomatous eyes, there are signs of hypoxia such as an increase of
HIF1-alpha. If, however, glaucomatous optic nerve damage is a hypoxic process,
why - Flammer asked - does a glaucomatous optic nerve with its characteristic
excavation looks so different from a papilla in an indisputably ischemic
condition such as an acute ischemic optic neuropathy (AION)?
The
answer is provided by the behavior of the glial cells, particularly the
astrocytes. In an acute hypoxia, as in AION, they are activated and proliferate
to finally form a glial scar. In glaucoma, increased IOP and/or hypoxia also
induce a slight and long-lasting activation of the astrocytes. Simultaneously,
an increase of oxidative stress causes these cells to die slowly and therefore
prevents the formation of a gliotic scar. The main cause of this local
oxidative stress is an instable oxygen supply of the mitochondria, e.g. due to
sleep apnea, but particularly due to an instable local blood flow. Blood flow
in turn is unstable if IOP fluctuates to a high level - or if the blood pressure
drops to a low level; both conditions will from time to time ovestress the
autoregulatory capacity. If the autoregulation itself is disturbed, a situation
which e.g. is often observed in patients with Flammer syndrome, fluctuation of
IOP or blood pressure even in the normal range causes unstable blood flow. As a
therapeutic consequence, Flammer recommends to treat the vascular dysregulation
and to reduce the challenges for autoregulation by keeping IOP and blood
pressure on an ideal level without major fluctuation.
Dr. Katarzyna Konieczka |
Flammer
syndrome: numerous symptoms, striking associations with various diseases
It
is rare in medicine that a living researcher or discoverer is honored by having
an entity being named after him - for example a syndrome. In the case of the
Flammer Syndrome (FS), there was little contradiction within the medical
community when the term came up around 2010. The discovery of a certain
phenotype, which was partly made with a criminalistic intuition, is too clearly
associated with the host of the Summit. Flammer initially coined the term
vascular dysregulation for conspicuous perfusion disorders in the eye that are
associated with characteristic findings in other parts of the body such as
vasoconstriction of the extremities (cold fingers). The discovery of the
syndrome was also made possible by many affected persons who contacted him,
suffering from the symptoms that are now described even in Wikipedia where the
term “Flammer syndrome” is described in several different languages. Since
these patients in many cases often travelled to Basel, Flammer and his
colleagues were able to constantly add material to their collection of
characteristic findings.
Dr.
Katarzyna Konieczka (Basel), a leading researcher in this field of FS, recalled
some of the characteristics of affected people:
-
Low blood pressure
-
Cold hands and feet
-
Extended time to fall asleep
-
Reduced sensation of thirst
-
Slightly increased endothelin 1 levels in plasma
-
Increased sensitivity to pain, odors and increased sensitivity to certain drugs
-
Reduced blood flow in nail fold microscopy, particularly after cooling
-
Reduced autoregulation of ocular blood flow
-
Increased retinal venous pressure
-
and many more
The
reaction pattern to certain stimuli such as cold, physical and emotional stress
or fast ascent to high altitudes is almost typical.
Ophthalmologically
important is the relatively frequent occurrence of normal pressure glaucoma in
people with FS. This is explained by the reduced auto-regulation of ocular
blood flow, an increased retinal venous pressure (RVP), a low blood pressure
and an increased activation of astrocytes in FS subjects.
Konieczka
reported further on a study she conducted together with colleagues in Warsaw,
Poland. They found that if glaucoma patients put one hand in cold water, the
visual fields worsened temporarily in those patients who were diagnosed with
FS, but not in patients without FS. In
another study, Konieczka analyzed the effect of glaucoma drops on the corneal
temperature of healthy individuals. Brimonidine but not latanoprost induced a
temporary cooling of the cornea. This effect was significantly greater in
people with FS than in people without FS. In subjects with FS, even a slight
contralateral cooling effect was observed. This impressively demonstrates the
greater drug sensitivity of people with FS.
Less
well researched yet is the relationship between FS and other eye and general
diseases. Konieczka summarized her own work and the present literature: FS is a
risk factor for retinal vascular occlusion in young subjects without classical
vascular risk factors, FS influences the manifestation and progression of
retinitis pigmentosa and of central serous chorioretinopathy. FS is also
associated with Susac syndrome, a rather rare microangiopathy characterized by
triad of vascular encephalopathy, sensorineural hearing loss and retinal
vascular occlusion. Patients with multiple sclerosis also have statistically
significantly more often the symptoms and signs of Flammer syndrome. Typically
they indicate that they had the FS symptoms already before they were diagnosed
with MS. This is also true for other autoimmune diseases, e.g. of the thyroid
gland. One hypothesis to explain such associations is the assumption that
subclinical microinfarctions, induced by vascular dysregulation, may trigger an
autoimmune response. To clarify all these relationships, more research is
needed. Under further investigation is the role of FS in the pathogenesis of
certain malignant tumors and their metastasis.
Central
serous chorioretinopathy: RPE detachment and vascular leakage of unknown
genesis
It
hit an ophthalmic surgeon in the middle of a complicated operation. The
colleague felt a sudden vision loss which was particularly dramatic in this
situation - another surgeon had to take over for him. This case was one of the
most striking that Prof. Christian Prünte (Basel) was able to report. Stress
was unmistakably a trigger and indeed the suffering often occurs under such
pressure and with type A personalities (which generally includes doctors).
According to Prünte, it is a condition that has undergone a change of name,
mainly thanks to the efforts of his long-standing Basel boss Josef Flammer:
instead of chorioretinitis centralis serosa, today the international literature
speaks of central serous chorioretinopathy (CSC). The pathogenesis is largely
unknown, but vascular dysregulation seems to be involved or even causally
leading. Patients can often be described as hyperactive, CSC can also be
associated with systemic steroid therapy. Indocyanine green angiography (ICG)
often shows multifocal congestions of the choroidal veins in the affected but
interestingly also in the seemingly unaffected eye. Research from Basel has
identified endothelin-1 (ET-1), a potent vasoconstrictor that is significantly
elevated in plasma, as one of the triggers for this flow disorder: this was the
case at least in a group of 22 patients with acute CSC in whom the ET-1 level
in the specific radioimmunoassay was 2.76 pg/ml on average compared to 1.50
pg/ml in a healthy control group of the same age.
The
accumulation of ICG and other macromolecular proteins in the area of RPE
(retinal pigment epithelium) elevation indicates a collapse of the vascular
barrier for high-molecular substances. Elevation of the pigment epithelium was
described as characteristic for the clinical picture. This was confirmed by new
imaging techniques such as High Definition Fast Scanning OCT. A very typical
finding is the chimney-like column of a leakage in angiography, the smokestack
in the macula, which is probably due to the lower specific gravity of the fluid
escaping from the subepithelial space. It appears that lysosomal enzymes are
involved in this collapse of the vascular barriers. Many question marks on pathogenesis
remain in this disease for which no causal therapy exists. Prünte also
attributed the greatest chance of success in the treatment of the often
self-limiting but also recurrent condition to photodynamic therapy (PDT).
Retinitis
pigmentosa: The genetic disease also associated with disorders of ocular
perfusion
According
to Dr. Karl-Georg Schmidt (Freienbach, CH), reduced ocular blood flow is also
present in retinitis pigmentosa. This phenotypically very heterogeneous
clinical picture, in which around 3,000 mutations in more than 70 genes have
been detected, shows a decrease in the ocular perfusion parameters depending on
the stage. While they are rarely affected in early stages, a reduction in
systolic top speed, among other things, has been shown in advanced stages.
Other vascular abnormalities found in RP patients are a decrease in perfusion
in the macula and optic nerve, a decrease in parafoveal vessel density but also
increased oxygen saturation in ocular vessels, particularly in retinal veins.
Endothelin-1 should also play a pathogenetic role here. Among the (modest)
therapeutic approaches documented in the literature against these vascular
characteristics of the disease are an improvement of macular blood flow under
topical unoproston therapy and a slowing of central visual field progression
under systemic administration of the calcium antagonist nilvaldipine.
In
the discussion, Flammer remarked that although the reduction of blood flow,
e.g. in the choroid, is obseved in RP patients mainly in the late phase, a
disturbed regulation of the retinal blood vessels can already be observed in
the very first stage.
Calcium
channel blockers to improve ocular microcirculation
The
potent vasoconstrictor endothelin-1 is also elevated in other ocular vascular
diseases - such as, for example, Prof. Teruyo Kida (Osaka) explained, in
retinal vein occlusions. In contrast to former assumptions, the veins are not
mechanically compressed but rather actively constricted, a phenomenon which
Flammer explained in his work with a local diffusion of vasoactive substances
from the arterial wall and its surroundings to the veins. According to the
Japanese ophthalmologist, anti-VEGF therapy in retinal branch vein occlusions
often leads also to a reduction in ET-1 levels, but not always: in some
patients, these levels even increase, which is accompanied by a lack of
functional therapy success. In an animal model it was shown that the choroidal
blood flow decreased after intravenous injection of ET-1 and the retinal veins
near to the optic nerve head constricted.
The
effect of endothelin-1 can be counteracted by administering calcium channel
blockers, as Prof. Stephan Krähenbühl, pharmacologist at the University of
Basel, explained. These substances, especially the group of dihydropyridines,
appear to improve ocular microcirculation in people with high ET-1 levels. In
Krähenbühl's view as an internist, it is however questinable whether this leads
to a functional benefit. The most recent publication from 2017 documented a slower
visual field progression in a group of 39 patients with NTG under nimodipine
and nifedipine therapy compared to a control group not treated with calcium
channel blockers. Possible side effects of dihydropyridines include: reddening
of the skin due to the vasodilatation which is desired in the eye, possibly in
combination with headache; peripheral edema, constipation and reflex
tachycardia may also occur.
In
the discussion Flammer noticed the following: a) In patients with vascular
dysregulation, CCBs should be dosed very low, e.g. 1 to 3 mg nifedipine per
day. A very low dose has even a better effect with much less side, b)
water-soluble CCBs, such as nifedipine or amlodipine, although they do not
cross the blood-brain barrier, reach the optic nerve head via the choroid and
usually have a better effect than fat-soluble CCBs, c) CCB studies using visual
fields as their main parameter were practically always positive, while studies
with blood flow blood flow as main parameter were partly negative. The reason
for this is the fact that (low dose) CCBs do not, ore only slightly increase
baseline blood flow but rather improve the regulation of blood flow, which is
the important factor in the protection of the visual fields.
According
to Prof. Richard Stodtmeister (Dresden), other drugs also have a positive
effect, particularly on retinal venous pressure (RVP), which is increased in
many diseases including glaucoma. RVP has recently risen to the rank of an
independent risk factor for the progression of glaucoma damage. Stodtmeister
presented the results of a Dresden study in which 14 glaucoma patients were
treated for 4 months with 50 mg pentaerithrityltetranitrate, a prodrug used in
cardiology to dilate the coronary vessels. The initial RVP was reduced under
therapy from approximately 45 mm Hg to an average of 28 mm Hg, resulting in an
improvement in ocular perfusion pressure, a desirable effect especially in NTG
patients.
Calcium
channel blockers: a therapeutic option for glaucoma beyond pressure reduction?
Dr.
Maneli Mozaffarieh (Zürich) explained the role of calcium channel blockers in
glaucoma in more detail. This option is particularly suitable in situations in
which classical glaucoma therapy - the reduction of IOP - reaches its limits,
for example in patients with visual field progression despite an OP in the low
teens. The active substances are applied at a central point of the pathogenetic
concept of glaucomatous optic neuropathy after Flammer, the unstable blood flow
in many glaucoma patients (especially those with NTG) and the resulting
processes of tissue remodeling and cell apoptosis. Mozaffarieh further
demonstrated that CCBs also reduce the retinal venous pressure, a pressure that
is particularly often increased in glaucoma patients with FS. This can also be
explained by the fact that the vasoconstrictive effect of ET-1 on the optic
nerve and other regions of the eye may be counteracted by calcium channel
blockers.
Flammer
and co-authors documented an improvement of the visual field, best visible on
the Bebie curves (the eponym, Hans Bebie, emeritus professor of theoretical
physics in Bern, was one of the participants of the Summit) under short-term
nifedipine therapy for the first time in 1987. A few years later, a slight but
lasting improvement in visual fields was observed, especially in patients with
Flammer syndrome under long-term nifedipine therapy. The patient group of a
Japanese study was comparatively large; 36 glaucoma patients received calcium
channel blockers and 74 patients formed a control group without this therapy -
the perimetric deterioration over a period of almost ten years was
significantly less pronounced with this medication than in the control group.
According to Mozaffarieh, calcium channel blockers also reduce oxidative
stress, probably by keeping the blood flow more constant.
A
comparable effect on retinal venous pressure was also achieved by a natural
active ingredient: borage, a medicinal and aromatic plant cultivated since the
Middle Ages. In patients with Flammer syndrome, RVP was reduced on average from
38.9 mm Hg to 32.5 mm Hg with virtually no change in IOP.
Retinal
venous pressure: a reliable measurement method
If
ophthalmologists look at the central fundus, they usually detect a spontaneous
vein pulse on the papilla. If this is not the case, the RVP is significantly
higher than the intraocular pressure, a predisposing situation for glaucoma,
which is estimated to be present in one third of glaucoma patients, as Gabriele
Fuhrmann (Jena) pointed out. However, increased retinal venous pressure is not
only a risk factor for glaucoma damage, but also for patients with diabetic
retinopathies and retinal vein occlusion. This parameter can be measured
reliably by gently increasing the eye pressure from the outside for a few seconds
with a dynamometer and the examiner documents the IOP at which the pulsation of
the veins starts – this artificially induced IOP corresponds to the retinal
venous pressure. Fuhrmann presented also a new method to increase IOP. A small
balloon resting in a frame, similar to a pair of glasses, is pressed into the
(anaesthetized) corner of the patient's eye. This balloon is gradually inflated
in order to increase the IOP. With this new method no contact with the cornea
is necessary and the optic is free for a simultaneous observation of the
fundus. A study in Dresden tests
presently the application under clinical conditions.
Vascular
dysregulation, optic nerve compartment syndrome and increased retinal venous
pressure: Aspects of the same underlying disease?
Dr
Katarzyna Konieczka (Basel) demonstrated that these three clinical pictures
often occur together, especially in NTG patients with Flammer syndrome. The
good news is that, at least in her study, these three entities improved
simultaneously under a combination therapy with magnesium and a very low dose
of Nifedipine.
Retinal
Vessel Analysis: Helpful Tool for Cardiologists as well
The
response of arterioles and venules in the retina to flickering light allows a
statement on vascular health in other organs. Dynamic retinal vascular analysis
has made the high-tech investigation, actually developed for ophthalmologists,
a helpful tool for cardiologists. According to Prof. Henner Hanssen (Basel),
alterations of the small retinal vessels measured with the Retinal Vessel
Analyzer are a warning signal. Both reduced responses to flickering light as
well constricted arteries and or dilated veins are risk indicators for arterial
hypertension, diabetes mellitus and obesity which may predict an increased
occurrence of heart attack, stroke and cardiac mortality. The dynamic retinal
vascular analysis (DVA), developed by Walthard Vilser (Jena), measures the
diameter of certain small retinal arteries and veins. With a 12.5 Hz or 8 Hz
optoelectrical flicker light, a stimulation is exercised which induces in
healthy retinal arteries and veins a dilatation.
According
to Hanssen's experience, the retinal vascular analysis not only detects
vascular alterations corresponding to already exiting diseases but also allow a
prediction of future cardio-vascular diseases and enable monitoring of the
effect of therapeutic interventions. For example, the Basel study group imposed
a 20-minute exercise program on children during school breaks, five days a week
for four weeks, and at the end of this period, compared with an inactive or
normally active control group (36 participants each), found a clear improvement
in the vascular parameters CRAE (central retinal vein equivalent) and, in
parallel, improved cognitive function.
Another
study focused on physically inactive seniors. A total of 160 participants
between 50 and 69 years of age underwent 12 weeks of High Intensity Training
(HIT); the first results of this yet unpublished study showed an improvement in
retinal vascular parameters after the program. According to the speaker, this
analysis is sensitive to the effect of treatment strategies and can also
document the success of an ADAM strategy (aggressive decrease of
atherosclerosis modifiers, a combination of diet, exercise and medication) in
cardiovascular high-risk patients.
Dr.
Matthias Nägele from the Department of Internal Medicine (Baden CH) documented
in patients with a well-adjusted, compensated heart failure a significantly
reduced flicker-induced arteriolar dilatation in the retina, without clear
changes in the width of brachial arteries after stimulation. This points,
according to Nägele, to a limited microvascular endothelial function in
patients with a normal macrovascular endothelial function. The reduction in
venous flicker-induced dilatation compared to dilatation in healthy individuals
was associated with echographic evidence of left ventricular stiffness and
pulmonary hypertension. An important cardiovascular risk factor,
hypercholesterolemia, was also associated with a significant reduction of
flicker-stimulated arteriolar dilatation. According to Nägele, retinal vascular
analysis may be a useful tool for cardiologists to assess the success of
vascular-targeted therapies in patients with heart failure.
No comments:
Post a Comment